Showing results (1351-1360 of 1,490) with videos related to

Sort By:
Pageof 149
Nature Communications|March 25, 2026
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trialAngela Damato, Riziero Esposito Abate, Simona Tessitore, et al.
Neoplasia (New York, N.Y.)|August 21, 2012
The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoformSara Cattelani, Giovanna Ferrari-Amorotti, Sara Galavotti, et al.
Oncotarget|September 19, 2015
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patientsBruno Vincenzi, Chiara Cremolini, Andrea Sartore-Bianchi, et al.
Oncogene|August 28, 2024
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical modelsF Pantano, S Simonetti, M Iuliani, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2026
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testingFabrizio Citarella, Francesco M Venanzi, Giulia Di Giovanni, et al.
Plos One|April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trialF Ciardiello, N Normanno, E Maiello, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Giuseppe Bronte, Paolo Bidoli, et al.
Frontiers in Oncology|May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerTomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
Pageof 149